Acumen Pharmaceuticals Key Fundamental And Technical Indicators

Stocks . USA . 
Stock . Acumen Pharmaceuticals
ABOS Stock  USD 2.52  0.04  1.61%   
Acumen Pharmaceuticals' core ratios cover the per-share, per-dollar, and per-asset metrics analysts watch. The current ratio is 37.21, showing the ability to cover short-term obligations. Cross-peer comparison of ratios provides context that standalone figures lack. As reflected in current metrics, Acumen Pharmaceuticals posts RSI reading of 49, between the standard 30 and 50 reference levels. Readings in this range remain below 50 without entering the sub-30 oversold zone.
Momentum
 Impartial
49
OversoldOverbought
As of the 6th of May, Acumen Pharmaceuticals maintains a quoted price of 2.52 per share. Short-term indicators show Mean Deviation of 3.63, downside deviation of 4.83, and Risk Adjusted Performance of 0.0394. The model measures trend continuation and reversal probability using historical patterns. Comparative analytics measure deviation from sector averages.
Cycles Operators Shifting Impulse Patterns Depth Overlaps Statistics Volatility Volume
Tracking Acumen Pharmaceuticals' financial statements over time enables identification of durable earnings growth. Core indicators shaping Acumen Pharmaceuticals' market valuation are listed below: Sound investing in Acumen Pharmaceuticals starts with understanding earnings trends and cash conversion cycles. Key indicators are shown below:
Acumen Pharmaceuticals does not currently have any fundamental trend indicators for analysis. Equity Screeners allow side-by-side comparison of key metrics across the investment universe. The screener organizes equities by user-defined financial parameters.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Acumen Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives and major shareholders may have access to non-public information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

Current Acumen Pharmaceuticals Shares Owned By Insiders
    
  6.60 %  
The Shares Owned By Insiders for Acumen Pharmaceuticals plays a role in the broader analysis that compares price to intrinsic value estimate. Checking Acumen Pharmaceuticals' market valuation against core benchmarks shows if the stock is priced for growth or value.
Competition

Acumen Pharmaceuticals Fundamental Drivers Relationships

Main Technical Indicators as of May 6, 2026

Cycle Indicators
Math Operators
Math Transform
Momentum Indicators
Overlap Studies
Pattern Recognition
Price Transform
Statistic Functions
Volatility Indicators
Volume Indicators
Risk Adjusted Performance0.0394
Market Risk Adjusted Performance0.0839
Mean Deviation3.63
Semi Deviation4.57
Downside Deviation4.83
Coefficient Of Variation3083.82
Standard Deviation4.6
Variance21.2
Information Ratio0.0328
Jensen Alpha0.1617
Total Risk Alpha0.1957
Sortino Ratio0.0313
Treynor Ratio0.0739
Maximum Drawdown22.33
Value At Risk-7.49
Potential Upside7.01
Downside Variance23.37
Semi Variance20.88
Expected Short fall-3.73
Skewness-0.06
Kurtosis-0.22

Daily Market Strength Indicators

Accumulation/Distribution and Balance of Power for Acumen Pharmaceuticals reveal whether buying or selling pressure dominates recent sessions. Balance of Power trending positive indicates that buyers are consistently closing Acumen Pharmaceuticals near session highs. These signals help explain whether price direction and session structure are moving together for Acumen Pharmaceuticals. Combine market strength readings with the price and volatility measures above for a more complete analytical picture of Acumen Pharmaceuticals.
Accumulation Distribution8002.92
Daily Balance Of Power0.5
Rate Of Daily Change1.02
Day Median Price2.51
Day Typical Price2.51
Price Action Indicator0.03
Period Momentum Indicator0.04
Relative Strength Index49.11

Basic Forecasting Models

Relative Strength Index values for Acumen measure the speed and magnitude of recent price changes. Recognizing these clusters in Acumen Pharmaceuticals' returns informs position size and stop-loss calibration. Candlestick pattern analysis of Acumen Stock daily data reveals short-term reversal or continuation signals. Identifying these patterns in Acumen Stock data supports better trade timing.
Naive Prediction
Simple Exponential Smoothing
Double Exponential Smoothing
Triple Exponential Smoothing
Simple Regression
Polynomial Regression
Simple Moving Average
4 Period Moving Average
8 Period Moving Average
20 Period Moving Average

Acumen Pharmaceuticals Related Equities

These stocks within the Health Care space are often compared to Acumen Pharmaceuticals by analysts and fund managers in the sector. Profit comparisons show whether Acumen Pharmaceuticals earns above or below average returns next to its peers. When Acumen Pharmaceuticals breaks from its peer group on a key metric, it often signals a firm-level change worth exploring. Weighing both financial metrics and softer factors when comparing these firms produces a more balanced assessment.
 Risk & Return  Correlation

Shares Owned By Insiders Peer Comparison

Analyzing Acumen Pharmaceuticals relative to its peers on Shares Owned By Insiders provides a clear view of competitive standing. Consistent deviation in Acumen Pharmaceuticals' Shares Owned By Insiders relative to peers may signal mispricing or competitive advantages. The range of Shares Owned By Insiders values across Acumen Pharmaceuticals peers indicates how much variation exists within the sector. This peer comparison supports a data-driven approach to evaluating Acumen Pharmaceuticals investment merit.
Acumen Pharmaceuticals is currently under evaluation in shares owned by insiders relative to competitors.

Important Fundamentals

Return On Equity TTM-0.96
Return On Asset TTM-0.43
Current Valuation95.01 M
Shares Outstanding72.23 M
Shares Owned By Insiders6.60 %
Shares Owned By Institutions58.60 %
Number Of Shares Shorted1.55 M
Price To Book TTM2.44 X
Price To Sales TTM538.78 X
Gross Profit TTM-104.89 M
EBITDA TTM-123.83 M
Net Income TTM-121.33 M
Cash And Equivalents TTM189.91 M
Cash Per Share TTM4.69 X
Total Debt TTM31.31 M
Current Ratio TTM37.21 X
Book Value Per Share TTM1.16 X
Cash Flow From Operations TTM-115.54 M
Short Ratio TTM1.63 X
Earnings Per Share-2.11 X
Price To Earnings To Growth-0.23 X
Target Price7.4
Number Of Employees60
Trailing Beta0.32
Market Capitalization TTM179.12 M
Total Asset TTM122.83 M
Retained Earnings TTM-446.46 M
Working Capital TTM92.25 M
Net Asset122.83 M

Financial Metrics, Fundamentals & Methodology

Understanding Acumen Pharmaceuticals starts with capital efficiency, profitability direction, and liquidity support. Earnings persistence matters because stable results usually support more defensible valuation assumptions. In recent filings, Acumen Pharmaceuticals reported EPS loss of 2.11, current ratio of 37.21 as of the latest reporting period.

Acumen Pharmaceuticals analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Income statement, balance sheet, and cash-flow values follow GAAP or IFRS conventions as reported.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.